Form Type: 4

Accession Number:	0001209191-23-046957
Date:	2023-08-21
Issuer:	SHOCKWAVE MEDICAL, INC. (SWAV)
Original Submission Date:

Reporting Person:

WATKINS FRANK T
C/O SHOCKWAVE MEDICAL, INC.
5403 BETSY ROSS DRIVE SANTA CLARA, CA 95054

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of Security	Transaction Date	2a. Deemed Execution Date	Transaction Code	Shares	Acquired or Disposed	Price per share	5. Amount of Securities Beneficially Owned Following Reported Transaction	6. Ownership Form Direct or Indirect	Nature of Indirect Ownership
COMMON STOCK	2023-08-21		M	3,000	a	$3.42	4,532	direct
COMMON STOCK	2023-08-21		S	237	d	$216.40	4,295	direct
COMMON STOCK	2023-08-21		S	400	d	$217.43	3,895	direct
COMMON STOCK	2023-08-21		S	1,200	d	$218.90	2,695	direct
COMMON STOCK	2023-08-21		S	811	d	$220.70	1,884	direct
COMMON STOCK	2023-08-21		S	352	d	$221.43	1,532	direct

Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security	Conversion or Exercise Price of Derivative Security	Transaction Date	Deemed Execution Date	Transaction Code	Number of Derivative Securities Acquired (A) or Disposed of (D)	Date Exercisable	Expiration Date	Title and Amount of Securities Underlying Derivative Security	Price of Derivative Security	Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership
STOCK OPTION	3.416	2023-08-21	deemed execution date	M	3,000 (d)		2027-05-09	common stock 3,000	$3.42	102,313	direct

Footnotes
ID	footnote
f1	all transactions reported here were effected pursuant to a rule 10b5-1 plan adopted by the reporting person on 12/7/2022.
f2	the price reported in column 4 is a weighted average price. the reported securities were sold in multiple transactions at prices ranging from $216.20 to $216.68. the reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within such range.
f3	the price reported in column 4 is a weighted average price. the reported securities were sold in multiple transactions at prices ranging from $217.28 to $218.07. the reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within such range.
f4	the price reported in column 4 is a weighted average price. the reported securities were sold in multiple transactions at prices ranging from $218.67 to $219.45. the reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within such range.
f5	the price reported in column 4 is a weighted average price. the reported securities were sold in multiple transactions at prices ranging from $220.29 to $221.19. the reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within such range.
f6	the price reported in column 4 is a weighted average price. the reported securities were sold in multiple transactions at prices ranging from $221.34 to $221.56. the reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within such range.
f7	twenty-five percent of the shares subject to the option vested on 2/25/18 and the balance of the shares vested in equal monthly installments thereafter for 36 months.

Elevate your investments